Advanced search
Publication Cover
International Reviews of Immunology Volume 31, 2012 - Issue 2
Submit an article Journal homepage
2,221
Views
159
CrossRef citations to date
0
Altmetric
Research Article

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

Joseph J. BuggyPharmacyclics, Inc., Sunnyvale, California, USACorrespondence[email protected]
, PhD &
Laurence EliasPharmacyclics, Inc., Sunnyvale, California, USA
, MD
Pages 119-132 | Accepted 04 Feb 2012, Published online: 26 Mar 2012

Citations (159)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (19)

Paolo Ghia, Monika Dlugosz-Danecka, Lydia Scarfò & Wojciech Jurczak. (2021) Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 62:5, pages 1066-1076.
Read now
Zhen Zhu, Lanlan Ling, Lezhong Qi, Yue Chong & Li Xue. (2020) Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer. OncoTargets and Therapy 13, pages 4113-4122.
Read now
R. Li, Y. Du & J. Shen. (2018) Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR. SAR and QSAR in Environmental Research 29:11, pages 847-873.
Read now
Kelly Valla, Christopher R. Flowers & Jean L. Koff. (2018) Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opinion on Investigational Drugs 27:6, pages 513-522.
Read now
Idanna Innocenti, Francesco Autore, Raffaella Pasquale, Francesca Morelli, Dimitar G Efremov & Luca Laurenti. (2017) Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology 10:12, pages 1069-1076.
Read now
David Tucker & Simon Rule. (2017) Novel agents in mantle cell lymphoma. Expert Review of Anticancer Therapy 17:6, pages 491-506.
Read now
Lakshminarayanan Nandagopal & Amitkumar Mehta. (2017) Treatment approaches of hard-to-treat non-Hodgkin lymphomas. Expert Review of Hematology 10:3, pages 259-273.
Read now
Jonas Paludo & Stephen M Ansell. (2016) Waldenström macroglobulinemia: biology, genetics, and therapy. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 49-58.
Read now
David L Tucker & Simon A Rule. (2015) A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management 11, pages 979-990.
Read now
Leila Kokabee, Xianhui Wang, Christopher J Sevinsky, Wei Lin Winnie Wang, Lindsay Cheu, Sridar V Chittur, Morteza Karimipoor, Martin Tenniswood & Douglas S Conklin. (2015) Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biology & Therapy 16:11, pages 1604-1615.
Read now
Rajshekhar Chakraborty, Prashant Kapoor, Stephen M Ansell & Morie A Gertz. (2015) Ibrutinib for the treatment of Waldenström macroglobulinemia. Expert Review of Hematology 8:5, pages 569-579.
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Nimish Shah, Claire Hutchinson & Simon Rule. (2014) Ibrutinib for the treatment of mantle cell lymphoma. Expert Review of Hematology 7:5, pages 521-531.
Read now
Gary Reynolds, Faye AH Cooles, John D Isaacs & Catharien MU Hilkens. (2014) Emerging immunotherapies for rheumatoid arthritis. Human Vaccines & Immunotherapeutics 10:4, pages 822-837.
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013) Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now
Julio C Chavez, Eva Sahakian & Javier Pinilla-Ibarz. (2013) Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evidence 8, pages 37-45.
Read now
Jacqueline Barrientos & Kanti Rai. (2013) Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 54:8, pages 1817-1820.
Read now
Ronald J. Hill, Yan Lou & Seng-Lai Tan. (2013) B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities. International Reviews of Immunology 32:4, pages 377-396.
Read now
Mary Faris. (2013) Atypical B Cell Receptor Signaling: Straddling Immune Diseases and Cancer. International Reviews of Immunology 32:4, pages 355-357.
Read now

Articles from other publishers (140)

Jing Wang, Ran Qin, Yanling Jin, Bili Xia & Jianqing Xu. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal 211 230 .
Cuicui Li, Litian Zhang, Qiqi Jin, Haoyun Jiang & Chongyang Wu. (2023) Role and application of chemokine CXCL13 in central nervous system lymphoma. Annals of Hematology.
Crossref
Keshav Taruneshwar Jha, Abhimannu Shome, Chahat, Viney Chawla & Pooja A. Chawla. (2023) Medicinal perspectives and structure-activity relationship studies of pyrimidine based Bruton’s tyrosine kinase inhibitors as potential anticancer agents. Process Biochemistry 132, pages 308-322.
Crossref
Wenjia Ren, Cheng Yue, Linjun Liu, Licheng Du, Ke Xu & Yubai Zhou. (2023) Overexpression of Bruton Tyrosine Kinase Inhibits the Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer Cells. Analytical Cellular Pathology 2023, pages 1-11.
Crossref
Jyoti Singh, Vipan Kumar, Pragati Silakari & Sandeep Kumar. (2022) Pyridazinones: A versatile scaffold in the development of potential target‐based novel anticancer agents. Journal of Heterocyclic Chemistry 60:6, pages 929-949.
Crossref
卓如 周. (2023) Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma. Advances in Clinical Medicine 13:01, pages 1083-1091.
Crossref
Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song & Jun Zhu. (2022) Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma. Hematological Oncology 40:5, pages 894-905.
Crossref
Gowri Gollu, Sowjanya Gummadi, Venkata Deepthi Vemuri, Swathi Nalla, Nalini Mathala & Sasikala Allam. (2022) Forced Degradation Study of Zanubrutinib: An LC–PDA and LC–MS Approach. Journal of Chromatographic Science 60:9, pages 807-816.
Crossref
Mubarak Al-Mansour. (2022) Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e1019-e1031.
Crossref
Dr Emma Leitinger & Dr Zane Kaplan. (2022) BTK Inhibitors in Haematology: Beyond B Cell Malignancies. Transfusion Medicine Reviews 36:4, pages 239-245.
Crossref
Shinya Rai, Yoshinori Tanizawa, Zhihong Cai, Yu-Jing Huang, Kaisa Taipale & Masaomi Tajimi. (2022) Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. Advances in Therapy 39:10, pages 4792-4807.
Crossref
Lucie Čermáková, Jakub Hofman, Lenka Laštovičková, Lucie Havlíčková, Ivona Špringrová, Eva Novotná & Vladimír Wsól. (2022) Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. Pharmaceutics 14:10, pages 1994.
Crossref
Debasis Das, Jingbing Wang & Jian Hong. (2022) Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives. Current Topics in Medicinal Chemistry 22:20, pages 1674-1691.
Crossref
Buyun Chen, Diansong Zhou, Hua Wei, Marmor Yotvat, Li Zhou, Jean Cheung, Nicole Sarvaria, Richard Lai, Shringi Sharma, Karthick Vishwanathan & Joseph Ware. (2022) Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British Journal of Clinical Pharmacology 88:8, pages 3716-3729.
Crossref
Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, Jeannine Madere, J. Greg Slatter, Terry Podoll, Karthick Vishwanathan, Thomas Marbury, William Smith, Richard A. Preston, Shringi Sharma & Joseph A. Ware. (2022) Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology 62:6, pages 812-822.
Crossref
Shukaib Arslan, Haris Ali, Mathew Mei, Guido Marcucci, Stephan Forman, Ryotaro Nakamura, Anthony Stein & Monzr M. Al Malki. (2022) Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transplantation 57:5, pages 830-833.
Crossref
Nelli Morgulchik, Foteini Athanasopoulou, Edmund Chu, Yoriko Lam & Nazila Kamaly. (2021) Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus 12:1.
Crossref
Ivana Milosevic. (2022) Resistance to targeted therapy in chronic lymphocytic leukemia. Medicinski pregled Medical review 75:Suppl. 1, pages 57-61.
Crossref
Ali Khader, Rozan Bokhari, Reza Hakimelahi, Christopher Scheirey, Jalil Afnan, Marta Braschi-Amirfarzan & Richard Thomas. (2022) A radiologist’s guide to novel anticancer therapies in the era of precision medicine. European Journal of Radiology Open 9, pages 100406.
Crossref
Ye Zhang, Peng Lu, Yan Zhou & Lifei Zhang. (2021) Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway. PeerJ 9, pages e12571.
Crossref
Xin Xu, Ting Wei, Weijie Zhong, Rosalind Ang, Ye Lei, Hui Zhang & Qingshan Li. (2021) Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma. Cancer Cell International 21:1.
Crossref
Karin Zattar Cecyn, Mariana Oliveira Marques, Milena Almendra Rodrigues, Fábio Nascimento Brito & Otávio Cesar Carvalho Guimarães Baiocchi. (2021) Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report. BLOOD RESEARCH 56:3, pages 197-201.
Crossref
Andrei A. Petrenko, Maria I. Kislova, Elena A. Dmitrieva & Eugene A. Nikitin. (2021) Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. Journal of Modern Oncology 23:2, pages 332-338.
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Xianhui Wang, Leila Kokabee, Mostafa Kokabee & Douglas S. Conklin. (2021) Bruton’s Tyrosine Kinase and Its Isoforms in Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Jung Mi Park, Seung Wook Yang, Wei Zhuang, Asim K. Bera, Yan Liu, Deepak Gurbani, Sergei J. von Hoyningen-Huene, Sadie Miki Sakurada, Haiyun Gan, Shondra M. Pruett-Miller, Kenneth D. Westover & Malia B. Potts. (2021) The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLOS Biology 19:6, pages e3001281.
Crossref
Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi, Hirohiko Shibayama, Junji Suzumiya, Kazuhito Yamamoto, Satoshi Ichikawa, Koji Kato, Kyoya Kumagai, Priti Patel, Sakura Iizumi, Nobuya Hayashi, Hisashi Kawasumi, Kosho Murayama & Hirokazu Nagai. (2021) Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study. Cancer Science 112:6, pages 2405-2415.
Crossref
Alexey V. Danilov & Daniel O. Persky. (2020) Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British Journal of Haematology 193:1, pages 15-25.
Crossref
Javier Torres-Jiménez, Víctor Albarrán-Fernández, Javier Pozas, María San Román-Gil, Jorge Esteban-Villarrubia, Alfredo Carrato, Adriana Rosero, Enrique Grande, Teresa Alonso-Gordoa & Javier Molina-Cerrillo. (2021) Novel Tyrosine Kinase Targets in Urothelial Carcinoma. International Journal of Molecular Sciences 22:2, pages 747.
Crossref
Kun Wang, Qiushi Xu & Hanbing Zhong. (2021) The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. Frontiers in Pharmacology 11.
Crossref
Max J. Gordon & Alexey V. Danilov. (2021) The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia. Therapeutic Advances in Hematology 12, pages 204062072198958.
Crossref
Meijing Liu, Xuelin Wang, Zheng Li, Rui Zhang, Juan Mu, Yanyu Jiang, Qi Deng & Lei Sun. (2020) Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro. Cancer Science 111:11, pages 4051-4060.
Crossref
Jizhen Liu, Musi Ji, Zhidong Li, Xun Xu, Lili Li, Huawen Li, Yuguang Tian & Xiaohua Su. (2020) A rapid UHPLC–MS/MS method for the quantification of ARQ531 in rat plasma: Validation and its application to a pharmacokinetic study. Biomedical Chromatography 34:11.
Crossref
Eun Lee, Hyewon Cho, Da Kyung Lee, JuHyun Ha, Byeong Jo Choi, Ji Hye Jeong, Jae-Ha Ryu, Jong Soon Kang & Raok Jeon. (2020) Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase. International Journal of Molecular Sciences 21:21, pages 8006.
Crossref
Yonghui Sun & Yu Rao. 2020. Protein Degradation with New Chemical Modalities. Protein Degradation with New Chemical Modalities 147 166 .
Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui, Yuchuan Zhu, Lei Huang, Dongling Hao, Zhibo Qi, Guanglong Sun, Weifeng Mao, Yan Pan, Liang Shen, Xin Li, Guoping Hu, Zhen Gong, Shuhua Han, Jian Li, Shuhui Chen, Ronghua Tu, Xuehai Wang & Chengde Wu. (2019) Discovery and Evaluation of Pyrazolo[3,4- d ]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor . ACS Medicinal Chemistry Letters 11:10, pages 1863-1868.
Crossref
Yan Leyfman, Timothy K. Erick, Sandeep S. Reddy, Sagar Galwankar, Prabath W.B. Nanayakkara, Salvatore Di Somma, Pushpa Sharma, Stanislaw P. Stawicki & Irshad H. Chaudry. (2020) Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Shock 54:4, pages 438-450.
Crossref
Rory McCulloch, Toby A. Eyre & Simon Rule. (2020) What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?. Hematology/Oncology Clinics of North America 34:5, pages 923-939.
Crossref
Antonio Giovanni Solimando, Tiziana Annese, Roberto Tamma, Giuseppe Ingravallo, Eugenio Maiorano, Angelo Vacca, Giorgina Specchia & Domenico Ribatti. (2020) New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers 12:7, pages 1869.
Crossref
Jason T. Romancik & Jonathon B. Cohen. (2020) Management of Older Adults with Mantle Cell Lymphoma. Drugs & Aging 37:7, pages 469-481.
Crossref
Jim S. Qin, Timothy G. Johnstone, Alex Baturevych, Ronald J. Hause, Seamus P. Ragan, Christopher R. Clouser, Jon C. Jones, Rafael Ponce, Cecile M. Krejsa, Ruth A. Salmon & Michael O. Ports. (2020) Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. Journal of Immunotherapy 43:4, pages 107-120.
Crossref
Aayushi Srivastava, Sara Giangiobbe, Abhishek Kumar, Nagarajan Paramasivam, Dagmara Dymerska, Wolfgang Behnisch, Mathias Witzens-Harig, Jan Lubinski, Kari Hemminki, Asta Försti & Obul Reddy Bandapalli. (2020) Identification of Familial Hodgkin Lymphoma Predisposing Genes Using Whole Genome Sequencing. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Fansheng Ran, Yang Liu, Shengping Yu, Kaiwen Guo, Wendi Tang, Xin Chen & Guisen Zhao. (2020) Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma. Bioorganic Chemistry 94, pages 103367.
Crossref
Nikki Blosser, Jennifer Jupp, Patrick Yau & Douglas Stewart. (2019) Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. Clinical Pharmacokinetics 59:1, pages 7-23.
Crossref
Susanne Gamperl, Gabriele Stefanzl, Barbara Peter, Dubravka Smiljkovic, Karin Bauer, Michael Willmann, Peter Valent & Emir Hadzijusufovic. (2019) Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Veterinary and Comparative Oncology 17:4, pages 553-561.
Crossref
Bartosz Puła, Aleksandra Gołos, Patryk Górniak & Krzysztof Jamroziak. (2019) Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers 11:12, pages 1834.
Crossref
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli & Michele Cea. (2019) The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica 105:10, pages 2420-2431.
Crossref
Wenzhi Ma, Yanyu Wang, Dongchen Chu & Hong Yan. (2019) 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors. Journal of Molecular Graphics and Modelling 92, pages 357-362.
Crossref
Clement Chung. (2019) Current targeted therapies in lymphomas. American Journal of Health-System Pharmacy 76:22, pages 1825-1834.
Crossref
Benjamin Diamond & Anita Kumar. (2019) Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America 33:4, pages 613-626.
Crossref
Jorge E. Cortes, Brian A. Jonas, Thorsten Graef, Ying Luan & Anthony S. Stein. (2019) Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:8, pages 509-515.e1.
Crossref
Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, Paula Cramer, Fatih Demirkan, Graeme Fraser, Nancy Bartlett, Marie-Sarah Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, Andre Goy, Siddhartha Ganguly, Mariya Salman, Angela Howes, Michelle Mahler, Giuseppe De Nicolao & Italo Poggesi. (2019) Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharmaceutical Research 36:7.
Crossref
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter & Nidal Al‐Huniti. (2019) Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP ‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach . CPT: Pharmacometrics & Systems Pharmacology 8:7, pages 489-499.
Crossref
Margaux Wiber, Elsa Maitre, Edouard Cornet, Véronique Salaün, Dina Naguib & Xavier Troussard. (2019) Variant form of hairy cell leukemia. Clinical Case Reports 7:6, pages 1161-1166.
Crossref
Fansheng Ran, Yang Liu, Daoguang Zhang, Meixia Liu & Guisen Zhao. (2019) Discovery of novel pyrazole derivatives as potential anticancer agents in MCL. Bioorganic & Medicinal Chemistry Letters 29:9, pages 1060-1064.
Crossref
Ali S. Abdelhameed, Amer M. Alanazi, Ahmed H. Bakheit, Eman S. Hassan, Rashed N. Herqash & Fahad M. Almutairi. (2019) Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies. International Journal of Biological Macromolecules 127, pages 536-543.
Crossref
Xinyu Li, Binyu Shi, Yu Teng, Yu Cheng, Huizhu Yang, Jiurong Li, Lianjian Wang, Siying He, Qidong You & Hua Xiang. (2019) Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. MedChemComm 10:2, pages 294-299.
Crossref
Makhdum Ahmed, Elizabeth Lorence, Jeffrey Wang, Dayoung Jung, Liang ZhangKrystle NomieMichael Wang. (2019) Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Science Signaling 12:567.
Crossref
Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi & J. Greg Slatter. (2019) Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. Drug Metabolism and Disposition 47:2, pages 145-154.
Crossref
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigón, Andrzej Hellmann, Bryone Kuss, David D F Ma, Fatih Demirkan, Münci Yağci, Netanel A Horowitz, Paula Marlton, Raul Cordoba, Tomasz Wrobel, Daniela Buglio, Michael Streit, Brendan P Hodkinson, Michael Schaffer, John Alvarez, Rob Ceulemans, Sriram Balasubramanian, Jan de Jong, Shean-Sheng Wang, Nele Fourneau & Wojciech Jurczak. (2019) Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. The Lancet Haematology 6:2, pages e67-e78.
Crossref
Vladimir Ivanovich Vorob'ev, V.A. Zherebtsova, E.I. Dubrovin, L.A. Bychenkova, Yu.B. Kochkareva, L.A. Mukha, V.L. Ivanova, N.K. Khuazheva & V.V. Ptushkin. (2019) Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice. Clinical oncohematology 12:2, pages 65-72.
Crossref
Tianfeng Li, Yi Deng, Yu Shi, Ruijun Tian, Yonglong Chen, Lin Zou, Julhash U. Kazi, Lars Rönnstrand, Bo Feng, Sun On Chan, Wai Yee Chan, Jianmin Sun & Hui Zhao. (2018) Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37:47, pages 6180-6194.
Crossref
Michael A. Spinner, Gaurav Varma & Ranjana H. Advani. (2018) Novel Approaches in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 32:5, pages 875-890.
Crossref
Sean D. ReiffElizabeth M. Muhowski, Daphne GuinnAmy Lehman, Catherine A. FabianCarolyn CheneyRose MantelLisa SmithAmy J. Johnson, Wendy B. Young, Adam R. Johnson, Lichuan Liu, John C. Byrd & Jennifer A. Woyach. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:10, pages 1039-1049.
Crossref
Zhen Zhang, Daoguang Zhang, Yang Liu, Dezhi Yang, Fansheng Ran, Michael L. Wang & Guisen Zhao. (2018) Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Archiv der Pharmazie 351:7, pages 1700369.
Crossref
Cecilia B Rosand, Kelly Valla, Christopher R Flowers & Jean L Koff. (2018) Effective management strategies for patients with marginal zone lymphoma. Future Oncology 14:12, pages 1213-1222.
Crossref
Chengyuan Liang, Danni Tian, Xiaodong Ren, Shunjun Ding, Minyi Jia, Minhang Xin & Suresh Thareja. (2018) The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. European Journal of Medicinal Chemistry 151, pages 315-326.
Crossref
Xiao Yan, Yile Zhou, Shujuan Huang, Xia Li, Mengxia Yu, Jiansong Huang, Jinghan Wang, Zhixin Ma, Jingrui Jin, Jiajia Pan, Chenying Li, Fenglin Li & Jie Jin. (2018) Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. Journal of Cancer Research and Clinical Oncology 144:4, pages 697-706.
Crossref
Xiaojun Huang, Lugui Qiu, Jie Jin, Daobin Zhou, Xiequn Chen, Ming Hou, Jianda Hu, Yu Hu, Xiaoyan Ke, Junmin Li, Yingmin Liang, Ting Liu, Yue Lv, Hanyun Ren, Aining Sun, Jianmin Wang, Chunting Zhao, Mariya Salman, Steven Sun, Angela Howes, Jingzhao Wang, Peng Wu & Jianyong Li. (2018) Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Medicine 7:4, pages 1043-1055.
Crossref
Paul G. Richardson, William I. Bensinger, Carol Ann Huff, Caitlin L. Costello, Nikoletta Lendvai, Jesus G. Berdeja, Larry D. AndersonJr.Jr., David S. Siegel, Daniel Lebovic, Sundar Jagannath, Jacob P. Laubach, Keith E. Stockerl-Goldstein, Long Kwei, Fong Clow, Laurence Elias, Zeena Salman, Thorsten Graef, Elizabeth Bilotti & Ravi Vij. (2018) Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology 180:6, pages 821-830.
Crossref
Rui‐Fang Sun, Qian‐Qian Yu & Ken H. Young. (2018) Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. Chronic Diseases and Translational Medicine 4:1, pages 29-44.
Crossref
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D Smith, Gandhi Damaj, Jeanette Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P Kater, Steven Le Gouill, Lucie Oberic, Taduesz Robak, Todd Covey, Richa Dua, Ahmed Hamdy, Xin Huang, Raquel Izumi, Priti Patel, Wayne Rothbaum, J Greg Slatter & Wojciech Jurczak. (2018) Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. The Lancet 391:10121, pages 659-667.
Crossref
Haiyang Chen, Peiran Song, Yanyan Diao, Yongjia Hao, Dou Dou, Wanqi Wang, Xiaoyu Fang, Yanling Wang, Zhenjiang Zhao, Jian Ding, Honglin Li, Hua Xie & Yufang Xu. (2018) Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors. MedChemComm 9:4, pages 697-704.
Crossref
Trent Peng Wang, John Harwood Scott & Stefan Klaus Barta. (2017) The evolving role of targeted biological agents in the management of indolent B-cell lymphomas. Therapeutic Advances in Hematology 8:12, pages 329-344.
Crossref
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, Nora Cavazos, Black Liu, Shiyi Yang, Fong Clow, Jenna D. Goldberg, Darrin Beaupre, Jessica Vermeulen, Mark Wildgust & Michael Wang. (2017) Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. British Journal of Haematology 179:3, pages 430-438.
Crossref
Yanli Wang, Yuze Sun, Ran Cao, Dan Liu, Yuting Xie, Li Li, Xiangbing Qi & Niu Huang. (2017) In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery. Journal of Medicinal Chemistry 60:20, pages 8552-8564.
Crossref
Jose D. Sandoval-Sus, Eduardo M. Sotomayor & Bijal D. Shah. (2017) Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematology/Oncology and Stem Cell Therapy 10:3, pages 99-115.
Crossref
Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner & Jennifer A. Woyach. (2017) The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research 23:11, pages 2831-2841.
Crossref
Ekaterina KimChristian HurtzStefan KoehrerZhiqiang WangSriram BalasubramanianBetty Y. Chang, Markus MüschenR. Eric DavisJan A. Burger. (2017) Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129:9, pages 1155-1165.
Crossref
Jingjing Wu, Mingzhi Zhang & Delong Liu. (2016) Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget 8:4, pages 7201-7207.
Crossref
E.A. Nikitin, E.A. Dmitrieva, M.A. Panteleev, E.L. Emelina, V.L. Ivanova, Yu.B. Kochkareva, E.G. Arshanskaya, I.E. Lazarev, E.E. Markova, L.A. Mukha, N.G. Novitskaya, M.M. Pankrashkina, V.V. Glazunova, A.V. Shubina, S.A. Chernysh, N.K. Khuazheva, E.V. Naumova, S.A. Lugovskaya, M.E. Pochtar', T.N. Obukhova, O.Yu. Vinogradova, G.E. Gendlin & V.V. Ptushkin. (2017) Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. Clinical oncohematology 10:3, pages 271-281.
Crossref
A Hamasy, Q Wang, K E M Blomberg, D K Mohammad, L Yu, M Vihinen, A Berglöf & C I E Smith. (2016) Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia 31:1, pages 177-185.
Crossref
Juliane Paul, Maurice Soujon, Antje M. Wengner, Sabine Zitzmann-Kolbe, Andrea Sturz, Katja Haike, Koh Hui Keng Magdalene, Sze Huey Tan, Martin Lange, Soo Yong Tan, Dominik Mumberg, Soon Thye Lim, Karl Ziegelbauer & Ningshu Liu. (2017) Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. Cancer Cell 31:1, pages 64-78.
Crossref
Jana Fečková Mihályová, Juraj Ďuraš, Jana Zuchnická, Michal Kaščák & Roman Hájek. (2016) Ibrutinib in hematoonkology. Klinická farmakologie a farmacie 30:3, pages 8-14.
Crossref
Xianhui Wang, Jason Wong, Christopher J. Sevinsky, Leila Kokabee, Faiza Khan, Yan Sun & Douglas S. Conklin. (2016) Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Molecular Cancer Therapeutics 15:9, pages 2198-2208.
Crossref
Todd M. Doran, Mohosin Sarkar & Thomas Kodadek. (2016) Chemical Tools To Monitor and Manipulate Adaptive Immune Responses. Journal of the American Chemical Society 138:19, pages 6076-6094.
Crossref
John C Allen, Fatima Talab & Joseph R Slupsky. (2016) Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?. International Journal of Hematologic Oncology 5:1, pages 37-53.
Crossref
Kami Maddocks & Jeffrey A Jones. (2016) Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 251-259.
Crossref
Cory M. Vela, Ali McBride, Samantha M. Jaglowski & Leslie A. Andritsos. (2016) Ibrutinib for treatment of chronic lymphocytic leukemia. American Journal of Health-System Pharmacy 73:6, pages 367-375.
Crossref
David L Tucker & Simon A Rule. (2016) Ibrutinib for mantle cell lymphoma. Future Oncology 12:4, pages 477-491.
Crossref
Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Ann Janssens, Jiri Mayer, Nancy L Bartlett, Marie-Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, Panagiots Panagiotidis, Andre Goy, Anthony Mato, Miguel A Pavlovsky, Claes Karlsson, Michelle Mahler, Mariya Salman, Steven Sun, Charles Phelps, Sriram Balasubramanian, Angela Howes & Michael Hallek. (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet Oncology 17:2, pages 200-211.
Crossref
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trneny, Fritz Offner, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Georg Hess, Isabelle Bence-Bruckler, Seok-Goo Cho, John Bothos, Jenna D Goldberg, Christopher Enny, Shana Traina, Sriram Balasubramanian, Nibedita Bandyopadhyay, Steven Sun, Jessica Vermeulen, Aleksandra Rizo & Simon Rule. (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. The Lancet 387:10020, pages 770-778.
Crossref
Michael L Wang, Hun Lee, Hubert Chuang, Nicolaus Wagner-Bartak, Frederick Hagemeister, Jason Westin, Luis Fayad, Felipe Samaniego, Francesco Turturro, Yasuhiro Oki, Wendy Chen, Maria Badillo, Krystle Nomie, Maria DeLa Rosa, Donglu Zhao, Laura Lam, Alicia Addison, Hui Zhang, Ken H Young, Shaoying Li, David Santos, L Jeffrey Medeiros, Richard Champlin, Jorge Romaguera & Leo Zhang. (2016) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet Oncology 17:1, pages 48-56.
Crossref
James Shen & Kevin R. Kelly. 2016. mTOR Inhibition for Cancer Therapy: Past, Present and Future. mTOR Inhibition for Cancer Therapy: Past, Present and Future 139 160 .
Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust, Samiyeh Price, Danelle James, Margaret Doyle, Samina Bari & Sen Hong Zhuang. (2015) Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Annals of the New York Academy of Sciences 1358:1, pages 82-94.
Crossref
Lesley-Ann Sutton & Richard Rosenquist. (2015) The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Seminars in Cancer Biology 34, pages 22-35.
Crossref
Samantha M. Jaglowski, Jeffrey A. JonesVeena Nagar, Joseph M. FlynnLeslie A. AndritsosKami J. MaddocksJennifer A. WoyachKristie A. BlumMichael R. GreverKelly SmuckerAmy S. RuppertNyla A. Heerema, Gerard Lozanski, Mona StefanosBrian Munneke, Jamie-Sue West, Jutta K. Neuenburg, Danelle F. James, Nathan Hall, Amy J. JohnsonJohn C. Byrd. (2015) Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 126:7, pages 842-850.
Crossref
Shuang Q. Zhang, Sonali M. Smith, Shuang Y. Zhang & Yue Lynn Wang. (2015) Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. British Journal of Haematology 170:4, pages 445-456.
Crossref
Anita Kumar. (2015) Novel Agents in Mantle Cell Lymphoma. Current Oncology Reports 17:8.
Crossref
Catherine Thieblemont. (2015) Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B. Bulletin du Cancer 102:6, pages S85-S90.
Crossref
Alberto Mussetti, Anita Kumar, Parastoo B. Dahi, Miguel-Angel Perales & Craig S. Sauter. (2015) Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Reviews 29:3, pages 143-152.
Crossref
Jan de Jong, Juthamas Sukbuntherng, Donna Skee, Joe Murphy, Susan O’Brien, John C. Byrd, Danelle James, Peter Hellemans, David J. Loury, Juhui Jiao, Vijay Chauhan & Erik Mannaert. (2015) The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemotherapy and Pharmacology 75:5, pages 907-916.
Crossref
Stanley C Jordan, Jua Choi & Ashley Vo. (2015) Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 7:4, pages 377-398.
Crossref
Mohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, Georg Aue, Nakhle Saba, Carsten U Niemann, Sarah E M Herman, Xin Tian, Gerald Marti, Susan Soto, Thomas E Hughes, Jade Jones, Andrew Lipsky, Stefania Pittaluga, Maryalice Stetler-Stevenson, Constance Yuan, Yuh Shan Lee, Lone B Pedersen, Christian H Geisler, Katherine R Calvo, Diane C Arthur, Irina Maric, Richard Childs, Neal S Young & Adrian Wiestner. (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. The Lancet Oncology 16:2, pages 169-176.
Crossref
Iván Fernández-Vega, Luis M. Quirós, Jorge Santos-Juanes, María Pane-Foix & Teresa Marafioti. (2014) Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Archiv 466:2, pages 229-235.
Crossref
Adrian Wiestner. (2014) BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology 2014:1, pages 125-134.
Crossref
Nicole Grabinski & Florian Ewald. (2014) Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Investigational New Drugs 32:6, pages 1096-1104.
Crossref
Clement Chung & Rosetta Lee. (2014) Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:12, pages 1298-1316.
Crossref
Jie Shao, John S. Markowitz, Di Bei & Guohua An. (2014) Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 103:12, pages 3810-3833.
Crossref
S E M Herman, C U Niemann, M Farooqui, J Jones, R Z Mustafa, A Lipsky, N Saba, S Martyr, S Soto, J Valdez, J A Gyamfi, I Maric, K R Calvo, L B Pedersen, C H Geisler, D Liu, G E Marti, G Aue & A Wiestner. (2014) Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28:11, pages 2188-2196.
Crossref
Natthakorn Rattanachartnarong, Siraprapa Tongkobpetch, Pantipa Chatchatee, Tassalapa Daengsuwan, Chupong Ittiwut, Kanya Suphapeetiporn & Vorasuk Shotelersuk. (2014) In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides. Archivum Immunologiae et Therapiae Experimentalis 62:5, pages 431-436.
Crossref
Jiao Ma, Pin Lu, Ailin Guo, Shuhua Cheng, Hongliang Zong, Peter Martin, Morton Coleman & Y. Lynn Wang. (2014) Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. British Journal of Haematology 166:6, pages 849-861.
Crossref
Loic Ysebaert & Anne-Sophie Michallet. (2014) Bruton's tyrosine kinase inhibitors. Current Opinion in Oncology 26:5, pages 463-468.
Crossref
Johanna Mondesir, Pierre Sujobert, Mark A Murakami, Marie-Anne Hospital, Didier Bouscary & Jerome Tamburini. (2014) Use of signaling pathways as therapeutic targets for blood cancer. International Journal of Hematologic Oncology 3:4, pages 275-288.
Crossref
R Bam, S U Venkateshaiah, S Khan, W Ling, S S Randal, X Li, Q Zhang, F van Rhee, B Barlogie, J Epstein & S Yaccoby. (2014) Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. Blood Cancer Journal 4:8, pages e234-e234.
Crossref
Akintunde Akinleye, Muhammad Furqan & Oluwaseyi Adekunle. (2014) Ibrutinib and Indolent B-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 253-260.
Crossref
Silvia Schenone, Marco Radi, Francesca Musumeci, Chiara Brullo & Maurizio Botta. (2014) Biologically Driven Synthesis of Pyrazolo[3,4- d ]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies . Chemical Reviews 114:14, pages 7189-7238.
Crossref
Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer A. Gyamfi, Stefania Pittaluga, Stella Chang, Betty Chang, Mohammed Farooqui & Adrian Wiestner. (2014) Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 123:21, pages 3286-3295.
Crossref
M A Kharfan-Dabaja, W G Wierda & L J N Cooper. (2013) Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 28:3, pages 507-517.
Crossref
Hiromichi Ebi, Carlotta Costa, Anthony C. Faber, Madhuri Nishtala, Hiroshi Kotani, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino-Kenudson, Cyril H. Benes & Jeffrey A. Engelman. (2013) PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences 110:52, pages 21124-21129.
Crossref
Akintunde Akinleye, Yamei Chen, Nikhil Mukhi, Yongping Song & Delong Liu. (2013) Ibrutinib and novel BTK inhibitors in clinical development. Journal of Hematology & Oncology 6:1.
Crossref
Mei Wu, Akintunde Akinleye & Xiongpeng Zhu. (2013) Novel agents for chronic lymphocytic leukemia. Journal of Hematology & Oncology 6:1.
Crossref
Carsten U. Niemann & Adrian Wiestner. (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Seminars in Cancer Biology 23:6, pages 410-421.
Crossref
Betty Y. ChangMichelle FrancescoMartin F. M. De Rooij, Padmaja MagadalaSusanne M. SteggerdaMin Mei HuangAnnemieke Kuil, Sarah E. M. Herman, Stella ChangSteven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. BuggyLaurence Elias. (2013) Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122:14, pages 2412-2424.
Crossref
Munevver Cinar, FaridSaei Hamedani, Zhicheng Mo, Bekir Cinar, Hesham M. Amin & Serhan Alkan. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leukemia Research 37:10, pages 1271-1277.
Crossref
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin M. Beaupre, Lori A. Kunkel & Kristie A. Blum. (2013) Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine 369:6, pages 507-516.
Crossref
L. Vargas, A. Hamasy, B. F. Nore & C. I. E. Smith. (2013) Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases. Scandinavian Journal of Immunology 78:2, pages 130-139.
Crossref
Jonathan H. Schatz, Elisa Oricchio, Soham D. Puvvada & H. Guido Wendel. (2013) Progress against follicular lymphoma. Current Opinion in Hematology 20:4, pages 320-326.
Crossref
Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bożena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy, Fong Clow, Darrin M. Beaupre, Lori Kunkel, Andre Goy, Kristie A. Blum, Wiktor Jędrzejczak & Michael L. Wang. (2013) Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza – wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA Encore. Acta Haematologica Polonica 44:3, pages 314-318.
Crossref
Rakesh Bam, Wen Ling, Sharmin Khan, Angela Pennisi, Sathisha Upparahalli Venkateshaiah, Xin Li, Frits van Rhee, Saad Usmani, Bart Barlogie, John Shaughnessy, Joshua Epstein & Shmuel Yaccoby. (2013) Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. American Journal of Hematology 88:6, pages 463-471.
Crossref
Seng-Lai Tan, Cheng Liao, Matthew C. Lucas, Christopher Stevenson & Julie A. DeMartino. (2013) Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders. Pharmacology & Therapeutics 138:2, pages 294-309.
Crossref
Yair Herishanu, Ben-Zion Katz, Andrew Lipsky & Adrian Wiestner. (2013) Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Hematology/Oncology Clinics of North America 27:2, pages 173-206.
Crossref
Adrian Wiestner. (2013) Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies. Journal of Clinical Oncology 31:1, pages 128-130.
Crossref
Robert D. Riehle, Sinziana Cornea & Alexei Degterev. 2013. Lipid-mediated Protein Signaling. Lipid-mediated Protein Signaling 105 139 .
Carsten U. Niemann, Jade Jones & Adrian Wiestner. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia 259 291 .
Adrian Wiestner. (2012) Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology 2012:1, pages 88-96.
Crossref
Adrian Wiestner. (2012) Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 120:24, pages 4684-4691.
Crossref
Caterina Carmi, Marco Mor, Pier Giorgio Petronini & Roberta R. Alfieri. (2012) Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochemical Pharmacology 84:11, pages 1388-1399.
Crossref
Michael Y. Choi & Thomas J. Kipps. (2012) Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies. The Cancer Journal 18:5, pages 404-410.
Crossref
Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song & Zhu Jun. (2022) Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.